APAC & Latin America Pharmaceutical Contract Manufacturing Market Summary
The Asia Pacific and Latin America pharmaceutical contract manufacturing market size was valued at USD 21.56 billion in 2025 and is projected to reach USD 40.71 billion by 2033, growing at a CAGR of 8.39% from 2026 to 2033. The industry is driven by the growing number of generic drug approvals, growing clinical and commercial emphasis on biologic medicines and their biosimilar counterparts, and a strengthening regulatory framework.
Key Market Trends & Insights
On the basis of type, the clinical segment accounted for the largest revenue share of 75.35% in 2025.
On the basis of molecule type, the small molecules segment held the largest market share in 2025.
On the basis of services, the regulatory/medical affairs segment is anticipated to grow at the fastest CAGR during the forecast period.
Market Size & Forecast
2025 Market Size: USD 21.56 Billion
2033 Projected Market Size: USD 40.71 Billion
CAGR (2026-2033): 8.39%
The growing number of generic drug approvals is driving significant demand for high-volume manufacturing and remains a major structural driver of the Asia Pacific and Latin America pharmaceutical contract manufacturing market. According to the U.S. FDA Office of Generic Drugs, the agency approved 956 abbreviated new drug applications (ANDAs) in 2023 and 694 ANDAs in 2024, reflecting robust development activity in the global generic drug space.
A significant portion of the global pharmaceutical supply chain is concentrated in India and China, where India accounts for approximately 48% of all active pharmaceutical ingredient (API) Drug Master Files (DMFs) and China contributes 18%. Latin America is emerging as a key regional production hub, supported by favorable government policies and investments in local manufacturing capacity. This concentration enables pharmaceutical companies to leverage cost-efficient, scalable, and compliant production solutions, meeting growing global demand while reducing time-to-market pressures. The combination of rising approvals and concentrated manufacturing capacity ensures sustained outsourcing activity in these high-growth regions.
Type Insights
On the basis of type, the market is classified into drug discovery, pre-clinical, and clinical. The clinical segment accounted for the largest revenue share of 75.35% in 2025. The clinical trials segment in pharmaceutical CRO is growing due to the increasing volume of drug development programs. Pharmaceutical companies are outsourcing clinical trials to CROs to gain access to specialized expertise, global trial networks, and advanced technologies, while also managing costs and operational efficiency.
The preclinical segment is anticipated to grow at the fastest CAGR during the forecast period. The preclinical segment is driven by multiple factors, such as scientific, regulatory, and economic factors. Preclinical studies play a crucial role in the drug development process, as they provide essential data on the safety, efficacy, and pharmacokinetics of new drug candidates before they can be tested in humans. Pharmaceutical companies require robust in vitro and in vivo studies and toxicology evaluations, all of which demand specialized expertise and advanced infrastructure that companies prefer to outsource to CROs.
Molecule Type Insights
On the basis of molecule type, the market is segregated into small molecules and large molecules. The small molecules segment held the largest market share in 2025. Small-molecule drug development continues to drive active drug development programs and sustained sponsor outsourcing across discovery and clinical stages. For instance, according to the U.S. Food and Drug Administration, in 2025, 46 novel drugs received approval from the U.S. FDA, among which 34 were small-molecule therapies. The continued presence of small-molecule drugs across oncology, metabolic disorders, and infectious disease indications supports sustained development activity and ongoing outsourcing demand for small-molecule-focused research programs.
The large molecule segment is anticipated to grow at the fastest CAGR during the forecast period. Large-molecule drug development, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies, continues to drive demand for specialized outsourced research and clinical services. These modalities involve complex bioanalytical workflows, immunogenicity assessment, and tailored clinical trial designs, expanding the scope of CRO engagement across preclinical evaluation and late-stage development.
Services Insights
On the basis of class type segment, the market is segregated into Project Management/Clinical Supply Management, Data Management, Regulatory/Medical Affairs, Medical Writing, Clinical Monitoring, Quality Management/ Assurance, Biostatistics, Investigator Payments, Laboratory, Patient and Site Recruitment, Technology, and Others. The Clinical Monitoring segment held the largest revenue size in the global market in 2025. The clinical trials need comprehensive monitoring for their success. Companies outsource this function to CROs with staff expertise and updated training programs. CROs conduct monitoring activities in accordance with the study protocols, International Council on Harmonization (ICH) guidelines, standard operating procedures, FDA regulations, and Good Clinical Practice (GCP).
The regulatory/medical affairs segment is anticipated to grow at the fastest CAGR during the forecast period. Regulatory and medical affairs services are one of the significant segments in the pharmaceutical CRO market as global clinical programs navigate increasingly complex and diverse regulatory landscapes. CRO regulatory teams support sponsors in interpreting and responding to evolving guidance from authorities, such as the FDA, EMA, and other regional agencies, particularly for accelerated approval pathways and breakthrough therapy designations.
Therapeutic Areas Insights
On the basis of therapeutic areas segment, the market is segregated into oncology, CNS disorders, infectious diseases, immunological disorders, cardiovascular disease, respiratory diseases, diabetes, ophthalmology, pain management, and others. The oncology segment held the largest revenue size in the global market in 2025. The growth is mainly due to the rising prevalence of cancer, including lung cancer, breast cancer, colorectal cancer, and prostate cancer. For instance, according to The Cancer Atlas, the number of cancer cases is expected to reach 29 million globally by 2040.
The CNS disorders segment is anticipated to grow at a considerable CAGR over the forecast period. The rising prevalence of neurological conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis is fueling demand for new drug development in the CNS (Central Nervous System) segment. According to the NCD Alliance, nearly 3.4 billion people are living with a neurological disorder worldwide.
Regional Insights
Asia Pacific pharmaceutical contract manufacturing market is projected to grow considerably. The region is also witnessing increased collaborations between CROs and local service providers, enabling broader therapeutic coverage and faster patient recruitment across diverse geographies. Countries such as China, Japan, and India are becoming preferred destinations for early-phase and late-phase trials because of strong regulatory reforms, advanced healthcare infrastructure, and high-quality clinical data.
China Pharmaceutical Contract Manufacturing Market Trends
China pharmaceutical contract manufacturing market is driven due to growing outsourcing among pharmaceutical companies, stringent standards around patient safety in clinical trials, easy access to a large pool of patients, and low operating costs. In addition, rising investments in the healthcare sector to upgrade infrastructure and boost advancements in technologies, along with the rising adoption of global R&D standards to meet international requirements, are key factors responsible for the growing demand for outsourcing services in China.
The pharmaceutical contract manufacturing market in Japan is expected to grow over the forecast period. Japan is one of the world’s leading markets in the pharmaceutical sector, and outsourcing services such as CROs play a pivotal role in enhancing the innovation of new drugs. The demand for CRO services in Japan is steadily increasing, driven by significant progress in drug development, increasing pipeline drug candidates, cost-effectiveness, and a proactive approach to competitive manufacturing techniques.
Latin America Pharmaceutical Contract Manufacturing Market Trends
The pharmaceutical contract manufacturing market in Latin America is rising as the number of clinical trials conducted across the region increases. Growing healthcare needs and expanding pharmaceutical research programs are encouraging sponsors to include Latin American countries in global clinical development plans.
Brazil pharmaceutical contract manufacturing market is driven due to various CRO activities. Brazil is increasingly engaging CROs to support study execution within the country. CRO activities focus on site management, patient recruitment, monitoring, and data management for multi-center studies at major hospitals and research institutions.
The pharmaceutical contract manufacturing market in Argentina is expected to grow over the forecast period. Pharmaceutical sponsors conducting clinical trials in Argentina rely on CROs to manage site coordination, patient recruitment, monitoring, and clinical data management across public hospitals, private clinics, and academic research centers. Pharmaceutical sponsors conducting clinical trials in Argentina rely on CROs to manage site coordination, patient recruitment, monitoring, and clinical data management across public hospitals, private clinics, and academic research centers.
Key Asia Pacific And Latin America Pharmaceutical Contract Manufacturing Company Insights
Key players operating in the Asia Pacific and Latin America pharmaceutical contract manufacturing market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.
Key Asia Pacific And Latin America Pharmaceutical Contract Manufacturing Companies:
WuXi STA
Piramal Pharma Solutions
Syngene International
Samsung Biologics
Jubilant Pharmova
Celltrion
Ajinomoto Bio-Pharma Services
Almac Group
Rubicon Research Pvt. Ltd.
Aurigene Pharmaceutical Services
Eurofarma Laboratórios S.A
Unither Pharmaceuticals
Fujifilm Diosynth Biotechnologies
Patheon (Thermo Fisher Scientific)
Pfizer
Recent Developments
In January 2026, Hanmi Pharmaceutical, part of Hanmi Science, is expanding the global reach of efpeglenatide, Korea’s first domestically developed GLP-1 therapy for obesity and metabolic diseases. On January 28, the company announced an exclusive distribution agreement with Laboratorios Sanfer in Mexico. Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales within Mexico.
Asia Pacific And Latin America Pharmaceutical Contract Manufacturing Market Report Scope
Report Attribute
Details
Market size value in 2026
USD 23.17 billion
Revenue forecast in 2033
USD 40.71 billion
Growth rate
CAGR of 8.39% from 2026 to 2033
Actual data
2021 – 2025
Forecast period
2026 – 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Type, molecule type, services, therapeutic area, region
Regional scope
Asia Pacific; Latin America
Country scope
Japan, China, India, Thailand, South Korea, Australia, Brazil, Argentina
Key companies profiled
WuXi STA; Piramal Pharma Solutions; Syngene International; Samsung Biologics; Jubilant Pharmova; Celltrion; Ajinomoto Bio-Pharma Services; Almac Group; Rubicon Research Pvt. Ltd.; Aurigene Pharmaceutical Services; Eurofarma Laboratórios S.A; Unither Pharmaceuticals; Fujifilm Diosynth Biotechnologies; Patheon (Thermo Fisher Scientific); Pfizer
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Asia Pacific And Latin America Pharmaceutical Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Asia Pacific and Latin America pharmaceutical contract manufacturing market report based on type, molecule type, services, therapeutic area, and region:
Type Outlook (Revenue, USD Million, 2021 – 2033)
Drug Discovery
Target Validation
Lead Identification
Lead Optimization
Pre-Clinical
Clinical
Phase I Trial Services
Phase II Trial Services
Phase III Trial Services
Phase IV Trial Services
Molecule Type Outlook (Revenue, USD Million, 2021 – 2033)
Small Molecules
Large Molecules
Services Outlook (Revenue, USD Million, 2021 – 2033)
Project Management/Clinical Supply Management
Data Management
Regulatory/Medical Affairs
Medical Writing
Clinical Monitoring
Quality Management/ Assurance
Bio-statistics
Investigator Payments
Laboratory
Patient And Site Recruitment
Technology
Others
Therapeutic Areas Outlook (Revenue, USD Million, 2021 – 2033)
Oncology
CNS Disorders
Infectious Diseases
Immunological Disorders
Cardiovascular Disease
Respiratory Diseases
Diabetes
Ophthalmology
Pain Management
Others
Regional Outlook (Revenue, USD Million, 2021 – 2033)
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America